{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:46Z","timestamp":1756902166005,"version":"3.44.0"},"reference-count":10,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>We report on a 16-year-old female who developed hypothermia as a result of a drug-drug interaction that produced supratherapeutic serum concentrations of clobazam. Although clobazam and its active metabolite (<jats:italic>N<\/jats:italic>-desmethylclobazam) are metabolized by cytochrome 2C19 (CYP2C19), literature suggests that clobazam-associated drug interactions involving this isoenzyme are not clinically relevant because of its wide therapeutic index. This report describes clobazam-associated hypothermia due to supratherapeutic serum concentrations of clobazam that resulted from the combination of 2 CYP2C19 inhibitors.<\/jats:p>","DOI":"10.5863\/1551-6776-24.2.156","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:31:02Z","timestamp":1555957862000},"page":"156-159","source":"Crossref","is-referenced-by-count":1,"title":["Hypothermia in an Adolescent Due to Probable Drug-Drug Interaction Involving Clobazam"],"prefix":"10.5863","volume":"24","author":[{"given":"Malinda G.","family":"Parman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy P.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"2","key":"i1551-6776-24-2-156-b1","series-title":"Ann Clin Psychiatry","first-page":"93","article-title":"Risk factors for hypothermia in psychiatric patients","volume":"8","year":"1999","unstructured":"Young\n              DM.\n            \n          \n          Risk factors for hypothermia in psychiatric patients. Ann Clin Psychiatry. 1999;8(2):93\u201397."},{"article-title":"Epilepsies: diagnosis and management. (NICE Clinical Guideline No. 137)","year":"2016","key":"i1551-6776-24-2-156-b2","unstructured":"National Institute for Health and Care Excellence. \n          Epilepsies: diagnosis and management. (NICE Clinical Guideline No. 137). 2016. https:\/\/www.nice.org.uk\/guidance\/cg137. Accessed October 19, 2018."},{"key":"i1551-6776-24-2-156-b3","series-title":"Epilepsy Behav Case Rep","first-page":"17","article-title":"Hypothermia associated with clobazam use in adult epilepsy","volume":"5","year":"2016","unstructured":"Gauthier\n              AC\n            , QuraishiIH, MattsonRH.\n          Hypothermia associated with clobazam use in adult epilepsy. Epilepsy Behav Case Rep. 2016;5:17\u201318."},{"key":"i1551-6776-24-2-156-b4","series-title":"Neurosci Med","first-page":"15","article-title":"Profound hypothermia secondary to clobazam use in epilepsy: a novel association","volume":"5","year":"2014","unstructured":"DiFazio\n              MP\n            , LavensteinB, DemarestS.\n          Profound hypothermia secondary to clobazam use in epilepsy: a novel association. Neurosci Med. 2014;5:15\u201319."},{"key":"i1551-6776-24-2-156-b5","series-title":"Drug Metab Dispos","first-page":"1279","article-title":"In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19","volume":"32","year":"2004","unstructured":"Giraud\n              C\n            , TranA, ReyE, \n          et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279\u20131286."},{"issue":"4","key":"i1551-6776-24-2-156-b6","series-title":"Pharmacotherapy","first-page":"340","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","year":"2012","unstructured":"Walzer\n              M\n            , BekerskyI, BlumRA, TolbertD.\n          Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340\u2013353."},{"issue":"2","key":"i1551-6776-24-2-156-b7","series-title":"J Pediatr Neurol","first-page":"219","article-title":"Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes","volume":"28","year":"2013","unstructured":"Wheless\n              JW\n            , PhelpsSJ.\n          Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Pediatr Neurol. 2013;28(2):219\u2013229."},{"issue":"1","key":"i1551-6776-24-2-156-b8","series-title":"Ther Drug Monit","first-page":"30","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies","volume":"35","year":"2013","unstructured":"De Leon\n              J\n            , SpinaE, DiazFJ.\n          Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35(1):30\u201347."},{"issue":"3","key":"i1551-6776-24-2-156-b9","series-title":"Antivir Ther","first-page":"589","article-title":"A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy","volume":"17","year":"2012","unstructured":"Naccarato\n              M\n            , YoongD, KovacsC, GoughK.\n          A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589\u2013592."},{"issue":"1","key":"i1551-6776-24-2-156-b10","series-title":"Clin Pharmacol Ther","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","year":"1981","unstructured":"Naranjo\n              CA\n            , BustoA, SellersEM, \n          et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(1):239\u2013245."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/2\/article-p156.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/24\/2\/156\/2466869\/1551-6776-24_2_156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/2\/article-p156.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/2\/article-p156.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:41:20Z","timestamp":1747356080000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/2\/article-p156.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":10,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-24.2.156","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2019]]}}}